MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

Phase 1
Completed
Conditions
Gastroesophageal Reflux
Interventions
Drug: Dexlansoprazole MR
First Posted Date
2009-02-19
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
36
Registration Number
NCT00847210

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

First Posted Date
2009-02-19
Last Posted Date
2012-02-07
Lead Sponsor
Takeda
Target Recruit Count
1711
Registration Number
NCT00847626

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Olmesartan medoxomil-hydrochlorothiazide
First Posted Date
2009-02-18
Last Posted Date
2012-03-13
Lead Sponsor
Takeda
Target Recruit Count
1085
Registration Number
NCT00846365

Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure

Phase 3
Terminated
Conditions
Heart Failure
Interventions
Drug: Candesartan and standard chronic heart disease therapy
Drug: Standard chronic heart disease therapy
First Posted Date
2009-02-13
Last Posted Date
2010-06-11
Lead Sponsor
Takeda
Target Recruit Count
571
Registration Number
NCT00843154

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

First Posted Date
2009-01-08
Last Posted Date
2012-02-07
Lead Sponsor
Takeda
Target Recruit Count
609
Registration Number
NCT00818883

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

Phase 2
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Leuprorelin
Drug: Flutamide
First Posted Date
2009-01-06
Last Posted Date
2015-07-29
Lead Sponsor
Takeda
Target Recruit Count
341
Registration Number
NCT00817739

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Phase 2
Completed
Conditions
Hyperlipidemias
Interventions
Drug: Lapaquistat acetate and fenofibrate
Drug: Fenofibrate
First Posted Date
2008-12-23
Last Posted Date
2012-05-24
Lead Sponsor
Takeda
Target Recruit Count
213
Registration Number
NCT00813527

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

Phase 3
Completed
Conditions
Ulcerative Colitis
Crohn's Disease
Interventions
Drug: Vedolizumab
First Posted Date
2008-11-14
Last Posted Date
2022-05-24
Lead Sponsor
Takeda
Target Recruit Count
2243
Registration Number
NCT00790933

Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

Phase 3
Completed
Conditions
Stomach Ulcer
Duodenal Ulcer
Interventions
Drug: Gefarnate
Drug: Lansoprazole
First Posted Date
2008-11-07
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
366
Registration Number
NCT00787254

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Phase 4
Completed
Conditions
Obesity
Hypertension
Interventions
Drug: Hydrochlorothiazide (HCT)
Drug: Candesartan and Hydrochlorothiazide
First Posted Date
2008-10-20
Last Posted Date
2012-08-08
Lead Sponsor
Takeda
Target Recruit Count
188
Registration Number
NCT00775814
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy